Delta, Kelowna, BC – June 25, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 434 (TSX: WEED) (NYSE: CGC) (CSE: ACTG.U) (TSXV: KHRN) (OTC: OWPC) (TSXV: WMD) (OTC: PHOT)
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and Acreage Holdings, Inc. (CSE: ACRG.U) (OTCQX: ACRGF) today announced they have entered into an agreement to amend the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, between Canopy Growth and Acreage.
Pursuant to the Arrangement Agreement, Canopy Growth agreed to acquire all of the issued and outstanding securities of Acreage pursuant to a plan of arrangement under the Business Corporations Act, contingent upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana and subject to the satisfaction or waiver of certain conditions to closing as set out in the Arrangement Agreement.
Acreage and Canopy Growth entered into the New Agreement to better align the terms of the Plan of Arrangement with broader market and economic factors, provide Acreage shareholders with an initial up-front payment in connection with the modification of Canopy Growth’s rights, including the extension of the term, and give Acreage shareholders the ability to participate in upside potential upon the Triggering Event.
KEY TRANSACTION HIGHLIGHTS & BENEFITS:
- Provides Up-Front Cash Payment. Canopy Growth will pay Acreage shareholders and certain convertible security holders an aggregate of US$37,500,000 (approximately US$0.30 per Existing Share (defined below) on an as converted basis, with the final amount to be received by each holder determined based on the number of Existing Shares into which all of the eligible securities are convertible at the close of business on the record date for the distribution).
- Attractive Valuation Premium. Acreage shareholders’ new Fixed Shares (defined below), each of which represents 70% of an Existing Share, will be entitled to receive 0.3048 of a Canopy Growth Share (defined below) for each Fixed Share held, representing a premium of approximately 120% to the June 24, 2020 closing price of the Existing Shares (defined below) on the Canadian Securities Exchange (the “CSE”).
- Provides Potential Upside with Floating Shares. Acreage shareholders will be entitled to participate in the long-term value created by Acreage, and in the U.S. cannabis industry generally, as a result of the Floating Shares (defined below) which Canopy Growth may acquire in the future upon the occurrence or waiver of the Triggering Event at a price based upon the 30-day volume-weighted average trading price of the Floating Shares on the CSE relative to the trading price of the Canopy Growth Shares on the NYSE at that time, subject to a minimum of US$6.41 per Floating Share.
- Alignment with Economic and Financial Market Conditions. Considering the challenging economic environment and increasingly tighter and volatile financial market conditions, particularly for cannabis companies, Acreage determined that the New Arrangement represents the best available prospect that is compliant with the terms of the Arrangement Agreement to maximize potential value for Acreage shareholders.
“The United States is going to be a core market for Canopy Growth and this New Agreement solidifies our path forward with Acreage,” said David Klein, Chief Executive Officer of Canopy Growth. “I am excited to bring our relationship with Acreage back to centre stage in our U.S. strategy and look forward to a time when the laws in the United States permit us to finalize this transaction as we march toward bringing our exciting beverage products to the US.”
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announced that it has entered into an agreement with Nimbus Health, a leading German distributor of medical cannabis products. Khiron branded EU GMP medical cannabis will soon be available in Germany for prescription by doctors and dispensation in pharmacies.
Tejinder Virk, President of Khiron Europe, commented: “This is a major milestone for our company. Following our recent entry into the United Kingdom, the expansion into Germany will greatly benefit patients who still suffer from inconsistent supply. Khiron is now well positioned to service this rapidly expanding market in Germany.”
The supply of EU GMP medical cannabis to Germany will be fully supported by the Company’s global medical education team, led by Dr. Maria Fernanda Arboleda, Khiron’s International Director for Medical Services. Dr. Arboleda is an Anesthesiologist, Pain and Palliative Care Physician. She completed a Spine-Regional Anesthesia Fellowship at the McGill University Health Center and a Post-Doctoral Research Fellow in Supportive Cancer Care and Medical Cannabis, at the Department of Oncology, McGill University, and at Sante Cannabis, a leading specialized cannabis clinic in Canada.
Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented: “Germany continues to be the European leader in medical cannabis, with other countries observing and adapting to the German regulatory model. The market is also differentiated with its large proportion of patient prescriptions fully reimbursed through insurance.”
One World Pharma Inc. (OTC: OWPC), a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, announced that the Company has commenced the selling of its characterized and registered seeds in Colombia.
One World Pharma has executed seed purchase agreements with three different Colombian growers and has begun shipments of seeds already. The agreements represent sales to entities growing both outdoor and in controlled environments.
One World Pharma previously announced that the Colombian Agricultural Institute (ICA) has approved the results of the seed characterization tests conducted by OWP of three non-psychoactive genetics in two sub-regions of the country. The approval established OWP as one of the few legal sellers of characterized hemp/CBD seeds for the Cauca and the Andina regions of Colombia, inclusive of greater Bogota and its surroundings. Additionally,
One World Pharma is now allowed to sell its seeds in international markets.
“While just the beginning of our entry into the revenue phase for One World Pharma, these agreements are a significant benchmark in the execution of our business plan,” stated Isiah Thomas, CEO and Vice-Chairman of One World Pharma. “Our first seed sale transactions affirm our trusted, licensed position in the Colombian marketplace and pave the way for future agreements and revenue.”
“We are intent on leveraging our position and quickly moving forward to continue our growth and expansion,” added Thomas. “The scale of our production and the expansion of our ingredient portfolio for commercial sale are also accelerating.”
WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) reported record preliminary unaudited revenues of $12 million(1) for the three month period ended March 31, 2020. The Company will report record sales growth representing the first full quarter of integration with Starseed Holdings Inc. (“Starseed”) following its acquisition in December 2019.
WeedMD will file its first quarter 2020 financial results after market on Tuesday July 14, 2020 and host a conference call with management the following day.
“Driven by Color Cannabis brand recognition, customer acquisition initiatives and a substantial sale of our outdoor-cultivated biomass, our first quarter 2020 net revenues of $12 million represents record-high sales from all channels – an increase of 325% quarter-over-quarter,” said Angelo Tsebelis, CEO, WeedMD. “With the benefits of our fully-integrated business model, scaled-up cultivation and production capabilities combined with our strong distribution channels, WeedMD is uniquely positioned for continued growth and a clear path to profitability. We are looking forward to sharing more during our conference call in July.”
The Company will host a conference call with management on Wednesday July 15, 2020 at 10 a.m. Eastern Time to discuss its financial results.
The call will be hosted by Angelo Tsebelis, CEO and Lincoln Greenidge, CFO. Management will be available for analyst and media questions following opening remarks.
GrowLife, Inc. (OTC: PHOT), one of the nation’s most recognized indoor cultivation product and service providers, today released the following letter from the Company’s Chief Executive Officer, Marco Hegyi.
I would like to take this opportunity to discuss some pertinent updates on what we are seeing in the market as well as our perception of the rapidly expanding demand for consumer CBD products. As we previously announced, GrowLife has been fully operational throughout the COVID-19 pandemic in order to serve our customers across the country with our leading line of hemp clones and commercial cloning products. The spring season is a very important time for hemp farmers and with cloning becoming more of the standard in CBD-rich hemp cultivation, it was imperative that we meet the demand for our products without delay. I am happy to report that our operations have continued to support the expanding demand for our products.
I am also pleased to share that demand for both cannabis and CBD products remains extremely high. While a delay in FDA approval for CBD and other cannabinoid-based consumer packaged goods has stalled further mainstream adoption, the demand for CBD products as ‘dietary supplements’ is higher than ever. On the legal Cannabis industry side, which was recently deemed an essential business, demand is still strong and the price per pound has stabilized if not increased, as in Colorado where it is over $1,000. As a result, demand for EZ-CLONE systems across the country remains higher than ever, especially this quarter. We are so excited by these trends and without getting into the specifics, I can share that I remain greatly confident in GrowLife and the EZ-CLONE business, especially in the areas of sales and operations.
On a more technical note, I wanted to address the on-going fluctuations and pressure we are experiencing in the market. As most people know, the market continues to see unprecedented swings and volatility. These market conditions, paired with some unexpected selling, has caused us to see a slide in the valuation of the company. While this is disappointing, the fundamentals of the company remain strong. We believe the market is undervaluing the Company based on its sales performance and we are well positioned to continue to capitalize on the expanding CBD-rich hemp market through our cloning equipment and proprietary hemp clone businesses. In spite of the COVID-19 situation, we have taken the necessary precautions as an essential business serving the demand of the industry, and continue to operate in a healthy manner with all our employees making solid contributions. I am prouder than ever in our team, suppliers and customers. I look forward to sharing the results of these efforts in our upcoming Q2 filings, which we expect to be filed on-time pending any further delays due to the pandemic.
We will continue to update you all as much as possible in the coming days and weeks. We appreciate our long-term shareholders, employees, and customers for their continued belief in our company. We hope everyone stays healthy and safe, and most importantly, positive through these historic times.
Chief Executive Officer
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android